SI2785349T2 - Kombinirano zdravljenje raka - Google Patents

Kombinirano zdravljenje raka

Info

Publication number
SI2785349T2
SI2785349T2 SI201231690T SI201231690T SI2785349T2 SI 2785349 T2 SI2785349 T2 SI 2785349T2 SI 201231690 T SI201231690 T SI 201231690T SI 201231690 T SI201231690 T SI 201231690T SI 2785349 T2 SI2785349 T2 SI 2785349T2
Authority
SI
Slovenia
Prior art keywords
cancer
combination treatment
treatment
combination
Prior art date
Application number
SI201231690T
Other languages
English (en)
Other versions
SI2785349T1 (sl
Inventor
Barry Robert Davies
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2785349(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI2785349T1 publication Critical patent/SI2785349T1/sl
Publication of SI2785349T2 publication Critical patent/SI2785349T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201231690T 2011-11-30 2012-11-30 Kombinirano zdravljenje raka SI2785349T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161564975P 2011-11-30 2011-11-30
EP12795842.9A EP2785349B2 (en) 2011-11-30 2012-11-30 Combination treatment of cancer
PCT/GB2012/052969 WO2013079964A1 (en) 2011-11-30 2012-11-30 Combination treatment of cancer

Publications (2)

Publication Number Publication Date
SI2785349T1 SI2785349T1 (sl) 2019-12-31
SI2785349T2 true SI2785349T2 (sl) 2023-01-31

Family

ID=47295082

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231690T SI2785349T2 (sl) 2011-11-30 2012-11-30 Kombinirano zdravljenje raka

Country Status (25)

Country Link
US (2) US20140329786A1 (sl)
EP (1) EP2785349B2 (sl)
JP (1) JP6309454B2 (sl)
KR (1) KR102035361B1 (sl)
CN (1) CN103945849B (sl)
AU (1) AU2012321110B2 (sl)
CA (1) CA2856646C (sl)
CY (1) CY1122624T1 (sl)
DK (1) DK2785349T4 (sl)
ES (1) ES2762250T5 (sl)
FI (1) FI2785349T4 (sl)
HK (1) HK1202253A1 (sl)
HR (1) HRP20191982T4 (sl)
HU (1) HUE046667T2 (sl)
IL (1) IL232530B (sl)
LT (1) LT2785349T (sl)
MX (1) MX367640B (sl)
MY (1) MY175800A (sl)
PL (1) PL2785349T5 (sl)
PT (1) PT2785349T (sl)
RS (1) RS59493B2 (sl)
RU (1) RU2640485C2 (sl)
SG (1) SG11201401471PA (sl)
SI (1) SI2785349T2 (sl)
WO (1) WO2013079964A1 (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
LT3628319T (lt) 2008-10-02 2024-03-25 Salix Pharmaceuticals, Inc. Hepatinės encefalopatijos gydymas rifaksiminu
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
RS57309B1 (sr) 2010-02-16 2018-08-31 Aragon Pharmaceuticals Inc Modulatori androgenih receptora i njihove upotrebe
US20130288984A1 (en) 2011-01-11 2013-10-31 Glaxosmithkline Llc Combination
AU2012358219A1 (en) * 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
AU2013204533B2 (en) * 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
MX371020B (es) * 2012-09-26 2020-01-13 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico.
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN105682662A (zh) 2013-03-14 2016-06-15 马里兰大学巴尔的摩校区 雄激素受体减量调节剂及其用途
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
BR112016006970A2 (pt) * 2013-10-01 2017-08-01 Novartis Ag enzalutamida em combinação com afuresertib para o tratamento de câncer
JP2016531884A (ja) * 2013-10-01 2016-10-13 ノバルティス アーゲー 組合せ物
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
ES2900149T3 (es) 2016-07-21 2022-03-16 Hadasit Med Res Service Combinaciones que comprenden antagonistas o inhibidores de AR para su uso en el tratamiento del glioblastoma
EP3527210B1 (en) 2016-12-16 2021-06-09 Kangpu Biopharmaceuticals, Ltd. Combined composition comprising a benzoheterocyclic compound and an androgen receptor pathway modulator and uses thereof
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
US20190091339A1 (en) * 2017-09-22 2019-03-28 Dispersol Technologies, Llc Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CN108486041A (zh) * 2018-03-28 2018-09-04 华南农业大学 PI3K/Akt信号通路在鸡胚成纤维细胞内对马立克氏病毒增殖的应用及其检测方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (sl) 1963-04-04 1900-01-01
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
AU668144B2 (en) 1992-03-31 1996-04-26 Btg International Limited 17-substituted steroids useful in cancer treatment
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
CA2249601A1 (en) 1996-04-03 1997-10-23 Thorsten E. Fisher Inhibitors of farnesyl-protein transferase
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
JP4865937B2 (ja) 1997-06-27 2012-02-01 アブラクシス バイオサイエンス、エルエルシー パクリタキセル製剤
CA2293621C (en) 1997-08-05 2003-12-30 Robert Lee Dow 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1090009A2 (en) 1998-06-04 2001-04-11 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
ES2318605T3 (es) 2000-06-26 2009-05-01 Pfizer Products Incorporated Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores.
JP3971299B2 (ja) 2000-08-31 2007-09-05 エフ．ホフマン−ラ ロシュ アーゲー α−１アドレナリン作動性拮抗薬としてのキナゾリン誘導体
EP1347980A4 (en) 2000-12-01 2005-02-09 Osi Pharm Inc RECEPTOR SPECIFIC COMPOUNDS OF ADENOSINE-A1, -A2A, AND-A3 AND USES THEREOF
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
UY27220A1 (es) 2001-03-23 2002-09-30 Aventis Pharma Sa Combinación de un taxano con una quinasa ciclina-dependiente
SI1474425T1 (sl) 2002-01-07 2006-10-31 Eisai Co Ltd Deazapurini in njihove uporabe
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
KR20050000544A (ko) 2002-05-17 2005-01-05 아방티 파르마 소시에테 아노님 유방암 및 난소암의 보조 요법에서도세탁셀/독소루비신/사이클로포스파미드의 용도
US8765783B2 (en) 2002-06-26 2014-07-01 Ono Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
EP1551410A2 (en) 2002-09-06 2005-07-13 Smithkline Beecham Corporation Novel compounds
EP1567495A4 (en) 2002-11-08 2007-10-31 Harvard College SMALL, WITH TECHNETIUM-99M AND RHENIUM-MARKED MEDIUM AND METHOD OF ILLUMINATING WOVEN FABRICS, ORGANS AND TUMORS
WO2004050656A1 (ja) 2002-12-04 2004-06-17 Eisai Co., Ltd. １，３−ジヒドロ−イミダゾール縮合環化合物
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
CA2518398A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
CA2507893A1 (en) 2003-04-21 2004-11-04 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
KR101223914B1 (ko) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제
WO2005063704A1 (ja) 2003-12-25 2005-07-14 Ono Pharmaceutical Co., Ltd. アゼチジン環化合物およびその医薬
EP1750727A2 (en) 2004-04-23 2007-02-14 Exelixis, Inc. Kinase modulators and methods of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006071819A1 (en) 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
EP1954263A2 (en) * 2005-02-23 2008-08-13 AstraZeneca AB Composition for increasing steady state plasma levels of bicalutamide
KR102324567B1 (ko) 2005-05-13 2021-11-09 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
CA2620389C (en) 2005-08-31 2014-06-17 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
DK1931321T3 (en) 2005-08-31 2019-04-15 Abraxis Bioscience Llc COMPOSITIONS CONTAINING VERY WATER-SOLUBLE PHARMACEUTICAL AND ANTIMICROBIAL AGENTS
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
US20090124610A1 (en) 2006-04-25 2009-05-14 Gordon Saxty Pharmaceutical compounds
JP2009534456A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
JP2009536161A (ja) 2006-04-25 2009-10-08 アステックス、セラピューティックス、リミテッド 医薬化合物
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
EP2815750A1 (en) 2006-12-21 2014-12-24 Vertex Pharmaceuticals Incorporated 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑
WO2010091306A1 (en) * 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
CA2749926A1 (en) 2009-02-10 2010-08-19 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
CN102481294A (zh) * 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
WO2011136828A1 (en) * 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia

Also Published As

Publication number Publication date
AU2012321110A1 (en) 2013-06-20
NZ625611A (en) 2016-10-28
DK2785349T3 (da) 2020-01-02
RU2014119713A (ru) 2016-01-27
JP6309454B2 (ja) 2018-04-11
MX367640B (es) 2019-08-29
RS59493B1 (sr) 2019-12-31
CN103945849B (zh) 2017-04-26
BR112014012261A2 (pt) 2017-06-13
MY175800A (en) 2020-07-09
US20140329786A1 (en) 2014-11-06
PT2785349T (pt) 2019-12-11
PL2785349T5 (pl) 2023-01-30
CY1122624T1 (el) 2021-03-12
HRP20191982T1 (hr) 2020-02-07
SG11201401471PA (en) 2014-08-28
KR102035361B1 (ko) 2019-11-08
DK2785349T4 (da) 2023-01-09
SI2785349T1 (sl) 2019-12-31
IL232530B (en) 2018-07-31
HRP20191982T4 (hr) 2023-01-06
ES2762250T3 (es) 2020-05-22
FI2785349T4 (fi) 2023-02-09
EP2785349B2 (en) 2022-11-09
EP2785349B1 (en) 2019-10-16
JP2015500225A (ja) 2015-01-05
AU2012321110B2 (en) 2014-10-23
EP2785349A1 (en) 2014-10-08
CN103945849A (zh) 2014-07-23
US9737540B2 (en) 2017-08-22
HUE046667T2 (hu) 2020-03-30
WO2013079964A1 (en) 2013-06-06
LT2785349T (lt) 2019-12-10
IL232530A0 (en) 2014-06-30
US20160151373A1 (en) 2016-06-02
HK1202253A1 (en) 2015-09-25
ES2762250T5 (es) 2023-01-05
RS59493B2 (sr) 2023-02-28
RU2640485C2 (ru) 2018-01-09
CA2856646A1 (en) 2013-06-06
KR20140098799A (ko) 2014-08-08
CA2856646C (en) 2020-01-14
PL2785349T3 (pl) 2020-03-31
MX2014006547A (es) 2014-07-09

Similar Documents

Publication Publication Date Title
HK1202253A1 (en) Combination treatment of cancer
EP2760452A4 (en) METHODS OF TREATING CANCER
EP2723384A4 (en) TREATMENT OF PROTEINOPATHIES
SG10201508495VA (en) Combination treatment of cancer
IL232890A0 (en) Immunogenic therapy for cancer
HK1202240A1 (en) Methods of treating cancer
ZA201307036B (en) Treatment of solid tumours
EP2788378A4 (en) ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
HK1214128A1 (zh) 癌症的治療
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
IL228430A0 (en) Cancer treatment
HK1205254A1 (en) Methods of treatment of cancer
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (en) Treatment of cancer
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
GB201217890D0 (en) Treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201121783D0 (en) Treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer
GB201208296D0 (en) Treatment of cancer
IL232266A0 (en) Cancer treatment methods
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer